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Abstract
Background: This study seeks to identify the prevalence of, and risk factors associated with, non-fatal overdose
among people currently injecting drugs (PWID) in St. Petersburg (Russia) and in Kohtla-Järve (Estonia).
Methods: Five hundred eighty-eight study participants in Kohtla-Järve (in 2012) and 811 in St. Petersburg
(in 2012–2013) were recruited using respondent driven sampling for interviewing and HIV testing.
Results: Three-quarters (76 %) of the current PWID were male. Participants from St. Petersburg were older (mean
age 32.1 vs. 29.6 years, p < 0.0001) and reported a longer average duration of injecting drugs (mean duration: 13.3
vs. 10.9 years, p < 0.0001). Main drugs injected were opioids (fentanyl in Kohtla-Järve, heroin in St Petersburg). HIV
prevalence was 63 % (95 % CI 59–67 %) in Kohtla-Järve and 56 % (95 % CI 52–59 %) in St. Petersburg. Two thirds of
the PWID in Kohtla-Järve and St. Petersburg reported ever having experienced a drug overdose involving loss of
consciousness or stopping breathing. In Kohtla-Järve, 28 % (95 % CI 24–31 %) of participants and, in St Petersburg, 16
% (95 % CI 14–19 %) of participants reported an overdose within the previous 12 months. Characteristics of injection
drug use practice (longer duration of injection drug use, main drug injected), correlates of high-risk injection behaviour
(higher injecting frequency, sharing), and problem alcohol use were associated with the risk of overdose within the
previous 12 months. The significant factors effects did not differ between the sites.
Conclusions: PWID are at high risk for overdose. Effective overdose prevention efforts at the public health scale are
therefore warranted.
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Background
A recent systematic review documented that mortality is
much higher in those who inject drugs than in the gen-
eral population [1]. Drug overdose is the leading cause
of death for people who inject drugs (PWID) [2]. Fatal
overdose, however, makes up only a small proportion of
overdose events, estimated at between 2 % and 4 % [3].
Non-fatal overdose carries significant morbidity [4] and
recent studies have identified previous non-fatal over-
dose experiences as a significant predictor of subsequent
non-fatal overdose [5, 6]. Of importance, research has
also documented significant overlap between the corre-
lates of fatal [7–11] and non-fatal overdoses [12]. An es-
timated 3.5 million people (1.5 % of the population)
inject drugs in Eastern Europe [13], a consequence of in-
jection drug use epidemics that started in the early
1990s and that fuelled explosive HIV epidemics begin-
ning from the late 1990s and early 2000s. In Russia,
overdose is a major cause of premature and preventable
death among drug users [14, 15]. One large, multi-city
study of PWID conducted in Russia reported that among
participating injection drug users, 59 % had experienced
an overdose, 81 % reported witnessing an overdose, and
15 % stated that a witnessed overdose had been fatal
[16]. For 2012, the average mortality rate due to opioid
overdoses in Europe was estimated at 17 deaths per
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million population aged 15–64, with the highest rate re-
ported from Estonia (19.1 deaths per 100 000) [17]. In
Estonia, overdose deaths are mostly related to the use of
fentanyls (fentanyl, 3-methyl-fentanyl), which are highly
potent synthetic opioids. Overdose mortality statistics
from Russia are less accurate, but by some estimates
there may be as many as 100,000 overdose deaths each
year (equal to 65 deaths per 100,000) [18]. According to
information from the Russian Federal Drug Control
Service in 2013, 28.7 people out of 100,000 in urban
populations died from overdose and drug related dis-
eases [18]. Most overdoses resulted from heroin or a
combination of heroin and alcohol, although the recent
appearance of methadone (a potent synthetic opioid) as
an illegal injected drug has resulted in a tenfold increase
in the number of overdoses (both fatal and non-fatal) re-
ported in St. Petersburg between 2010 and 2012 [19, 20].
Less attention has been paid to non-fatal overdoses.
Some data on factors contributing to the overdose risk
are available in Russia [15, 16, 21] but they are scant for
Estonia. In a small sample of 60 PWID from St. Peters-
burg, Grau et al. (2009) [15] found that 27 (45 %) re-
ported experiencing a non-fatal overdose in the year
prior to being interviewed. Walley et al. (2014) [21] found
that in clinical populations studied in St. Petersburg, 16 %
of HIV infected individual who both injected drugs and
were heavy drinkers reported having had a non-fatal over-
dose in the past 3 months. They also found that higher
injection frequency together with being on antiretroviral
therapy (ART) were associated with experiencing an
overdose.
The timing and trajectory of HIV epidemics in Estonia
and Russia have been similar, driven by transmission
among people who inject drugs, most commonly opi-
oids. Despite the surface similarities in the nature of
their HIV epidemics, structural differences between
Russia and Estonia may shape the risk profiles for drug
overdose. This includes significant differences in the
type of opioids used by PWID in Estonia, where fen-
tanyl is most commonly injected, and St. Petersburg,
where heroin injection is most common. In addition,
Estonia but not St. Petersburg provides low-threshold
HIV prevention and care for people who inject drugs,
most notably government-established and funded opi-
oid substitution and harm reduction programs. Specif-
ically, the Estonian system of care has incorporated
evidence-based public health practices, including syringe
exchange programs, for approximately 10 years, featuring
extensive collaboration between the government and non-
governmental organizations [22]. It has been estimated
that approximately 120 syringes per PWID per year have
been distributed since 2008 in Estonia [23]. Antiretroviral
treatment (ART) is available free of charge to all patients
in need, including those without health insurance. Studies
conducted in Estonia have documented that in recent
years over 40 % of PWID who have HIV are receiving
ART [23].
In contrast, opioid substitution is illegal in Russia, harm
reduction is supported neither by the Russian federal
government nor most regional governments, and Russian
police sometimes interfere with existing harm reduction
services [24]. Syringe exchange programs, where they
exist, are generally run by non-governmental organiza-
tions operating without much political or financial sup-
port [25]. Despite the fact that Russia doubled funding for
antiretroviral therapy in 2007, in the years that followed,
as few as 1 % of people who inject drugs who needed such
treatment have received it [26].
The current study sought to identify risk factors asso-
ciated with non-fatal overdose among current injection
drug users in St. Petersburg (Russia) and in Kohtla-Järve
(Estonia) who were not recruited from HIV or drug
treatment clinics. Both cities are administrative centres
for the respective (and adjoining) areas of Estonia (North
East County) and Russia (Leningradskaya Oblast). The
two sites were selected to obtain additional information
on factors related to overdose risk by contrasting find-
ings from different circumstances of drug use and harm
reduction approaches in those two sites.
Methods
Study sample
At both sites, we conducted cross sectional studies
among current PWID defined as persons reporting
injecting drugs in the past 4 weeks. Recruitment for an
interviewer-administered risk behaviour survey and HIV
testing was carried out through respondent-driven sam-
pling (RDS) as described in prior studies [27, 28]. Study
participation was anonymous. Participants had to be 18
years or older, speak Russian or (in Estonia) Estonian,
and be able to provide informed consent. Surveys were
administered by a team of trained fieldworkers, in confi-
dence, in Kohtla-Järve in rooms of the needle and syringe
program (NSP) and in St. Petersburg, at 7 independent re-
cruitment locations across regions of the city served by
outreach vans. Recruitment began with the non-random
selection of a small number of ‘seeds’ representing diverse
PWID types (by gender, main type of drug used, and HIV
status). A dual incentive approach (primary incentive for
participation in the study and a secondary incentive for
each eligible person recruited to the study) was used. To
assure eligibility, participants were asked to show evidence
of injection stigmata. If this was not possible (for example
if injections were made in the groin or if the respondent
was not a regular injector so that fresh stigmata were not
visible) potential participants were asked questions to as-
certain their familiarity with injecting drug use practices
before the start of the interview. All interviewers were
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familiar with the process of injecting and were able to dis-
cern appropriate responses.
The study questionnaire for both sites was based on
the WHO Drug Injecting Study Phase II survey (version
2b(rev.2)) [29] originally developed to collect risk behav-
iour data from PWID, and therefore contained similar
questions on key socio-demographic and behavioural
characteristics of drug injection (duration of injecting,
injection frequency, main drug injected, multi-drug use,
sharing within the last 4 weeks), problem alcohol use
(CAGE score) [30], assessment of mental health status
(Mental health inventory 5, (MHI-5)) [31, 32], and use
of harm reduction and prevention and drug treatment
services, history of incarceration, and HIV testing and
care. The instrument was modified to obtain information
on the illicit drugs known to be available in St. Petersburg
(Russia) and in Kohtla-Järve (Estonia), on experienced and
witnessed drug overdoses, and on internalized and experi-
enced stigma.
HIV counselling was provided, and a specimen was
collected for HIV testing. In Kohtla-Järve, venous blood
was tested with commercially available kits for HIV anti-
bodies (ADVIA Centaur HIV Antigen/Antibody Combo
Assay, Siemens Healthcare Diagnostics), and for those
testing HIV positive on the screening test, the diagnosis
was confirmed using INNO LIA HIV I/II Score Western
blot (Fujirebio Europe) and results were reported back
to participants). In St. Petersburg, rapid oral HIV testing
was used (OraQuick ADVANCE® Rapid HIV-1/2 Anti-
body Test, OraSure Technologies Inc.) and those testing
positive were referred to the City AIDS Center for con-
firmatory testing.
In Estonia, data collection was conducted from June to
August 2012 and in St Petersburg from November 2012
to June 2013.
Ethical approval was obtained from the Ethics Review
Board of the University of Tartu (Estonia), the Institutional
Review Board at NGO Stellit in St. Petersburg (Russian
Federation), and the Human Investigation Committee at
Yale University (USA).
Data analysis
Descriptive statistics were used to summarize the data by
site. The Pearson chi-squared test (for categorical vari-
ables) and t-test with unequal variances (for continuous
variables with normal distribution) or Wilcoxon rank-sum
test (for continuous variables with non-normal distribu-
tion) were used to explore differences between the sites.
The proportion of participants self-reporting non-fatal
overdose within the last 12 months (defined in the ques-
tionnaire as having “lost consciousness or stopped
breathing as a result of taking drugs”) was calculated.
This overdose definition probably restricts the accounts
to opioid-related overdose [33]. This focus was made to
acknowledge the fact that the overwhelming majority
(>90 %) of deaths related to injection drug use in the re-
gions studied are related to the opioids use [16, 34, 35]
Factors associated with report of non-fatal overdose
within the last 12 months were examined separately for
both of the sites using univariable and multivariable
logistic regression, from which odds ratios (OR) and ad-
justed OR (AOR), with corresponding 95 % confidence
intervals (CIs), were calculated. In addition to age and
gender, all factors associated with the outcome variable
in the univariate analysis at p < 0.05 at either site were
included in multivariable models. So, the same factors
were included in both multiple regression models, to
promote comparison between sites. Due to different
drug profiles, main drug for injecting was dichotomised
for both sites (opioids vs. other) to facilitate comparison
of multivariable analysis between the sites. We further
tested whether the significant factors effects were signifi-
cantly different for the sites by providing ratios of respect-
ive ORs with corresponding 95 % CIs. We determined
statistical significance using the penalized maximum likeli-
hood ratio test statistic [36].
Results
Sample characteristics by city
Table 1 presents the characteristics of the 588 study
participants recruited in Kohtla-Järve and 811 in St.
Petersburg by city. Across the two sites, three quarters
of the current PWID were male. Participants from St.
Petersburg tended to be older (p < 0.0001).
The participants in St. Petersburg reported a signifi-
cantly longer duration of injecting drugs (p < 0.0001),
and the proportion of those injecting daily or more fre-
quently was higher in St. Petersburg (p < 0.0001). For
both sites opioids were the main injection drugs, however
in Kohtla-Järve the synthetic opioid fentanyl was the most
common main drug injected (reported by 62 %, followed
by amphetamine, 35 %) whereas in St. Petersburg, heroin
was named as the main drug for injecting by 69 % of par-
ticipants (followed by another opioid, methadone, 27 %).
(Of note, fentanyl injected in Kohtla-Järve and methadone
injected in St. Petersburg are not diverted prescription
medicines; these products appear to be locally synthesized
directly for sale in illegal markets). Slightly over one-third
of PWIDs at both sites reported recent injections of more
than one drug. Concurrent with injection, consumption of
drugs by other means was significantly more frequent in
Kohtla-Järve than in St Petersburg (p < 0.0001). In Estonia,
of those reporting non-injection drug use in addition to
injecting (n = 246), oral use was reported by 73 % for am-
phetamine, 50 % for methylenedioxy-methamphetamine
(“ecstasy”), 24 % for fentanyl, 22 % for cocaine, and 15 %
for methamphetamine. Few respondents reported using
benzodiazepines (n = 10). In St Petersburg, the main non-
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Table 1 Socio-demographic, injection drug use, HIV prevalence and care and environmental characteristics of current injection drug
users participating and the prevalence of self-reported non lethal overdose within the last 12 months from cross sectional studies in
Kohtla-Järve, Estonia (in 2012) and St Petersburg, Russia (in 2012 – 2013)
Kohtla-Järve (Estonia), N = 588 St Petersburg (Russia), N = 811
Characteristics n % Overdose last 12 months (%) n % Overdose last 12 months (%)
Socio-demographic indicators
Age p = 0.134 p = 0.337
29 or less 295 50 % 25 % 245 30 % 18 %
30 or more 293 50 % 30 % 566 70 % 15 %
Gender p = 0.833 p = 0.423
Male 435 74 % 27 % 631 78 % 16 %
Female 152 26 % 28 % 180 22 % 18 %
Main source of income (last 6 months) p = 0.239 p = 0.021
Work (full/part time) 192 33 % 23 % 590 73 % 14 %
Social benefits 263 45 % 30 % 22 3 % 14 %
Other 127 22 % 31 % 199 25 % 23 %
Drug use characteristics
Duration of injecting p < 0.001 p = 0.008
< = 9 years 230 39 % 16 % 170 21 % 9 %
= > 10 years 356 61 % 35 % 640 79 % 18 %
Frequency of injecting (last 4 weeks) p < 0.001 p < 0.001
< Daily 447 76 % 24 % 524 65 % 11 %
Daily + 139 24 % 40 % 287 35 % 26 %
Main drug injected (last 4 weeks) p < 0.001 p = 0.116
Amphetamine 195 35 % 14 % 27 3 % 4 %
Fentanyl 350 62 % 34 % 4 0 % 25 %
Heroin 1 0 % 563 69 % 18 %
Methadone 0 0 % 217 27 % 14 %
Injecting multiple drugs (last 4 weeks) p = 0.124 p = 0.003
No 378 64 % 25 % 495 61 % 8 %
Yes 210 36 % 31 % 316 39 % 21 %
Non-injecting drug use (last 4 weeks) p = 0.575 p = 0.037
No 324 57 % 27 % 755 93 % 15 %
Yes 246 43 % 29 % 56 7 % 27 %
Sharing (last 4 weeks) p < 0.001 p < 0.001
No 492 85 % 24 % 277 34 % 7 %
Yes 88 15 % 49 % 534 66 % 21 %
Problem alcohol use p = 0.009 p < 0.001
No 247 42 % 22 % 275 34 % 8 %
Yes 341 58 % 32 % 536 66 % 21 %
Mental health (MHI 5) p = 0.003 p < 0.001
> = 52 362 62 % 23 % 536 66 % 13 %
<52 221 38 % 35 % 275 34 % 23 %
Structural (environmental) characteristics
Homelessness (current) p = 0.619 p = 0.454
No 583 99 % 27 % 798 98 % 16 %
Yes 5 1 % 40 % 13 2 % 14 %
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injected substances used were heroin and amphetamine
(reported by 45 % and 79 %, respectively, of the 56 people
using drugs other than by injection).
Two-thirds of the respondents reported problem
alcohol use (according to the CAGE score) and one
third of the sample reported clinically significant
psychological distress/mental health problems (MHI
5 scores < 52) [32].
The proportion of participants who had been in
prison was higher in Kohtla-Järve (p < 0.0001) as was
the proportion of those receiving drug treatment at the
time of the study (p < 0.0001). Of the participants in
drug treatment during the study participation in
Estonia, the majority (92 %) were receiving methadone
substitution treatment.
Based on testing, HIV prevalence was 63 % (95 % CI
59–67 %) in Kohtla-Järve and 56 % (95 % CI 52–59 %)
in St. Petersburg. Of those who were HIV-positive, 33 %
were on ART in Kohtla-Järve compared with 10 % in St.
Petersburg (p < 0.0001).
Two-thirds of the PWID in Kohtla-Järve (n = 377)
and St. Petersburg (n = 527) (64 % and 65 %, respect-
ively) reported ever having had a drug overdose involv-
ing loss of consciousness or stopping breathing. In
Kohtla-Järve, 162 (28 %, 95 % CI 24–31 %) participants
and in St Petersburg, 132 (16 %, 95 % CI 14–19 %) of
participants reported having a drug overdose within
the previous 12 months (p < 0.0001).
Risk factors associated with non-lethal overdose within
the last 12 months
Univariate analysis
The analysis for both cities are presented in Table 1.
In Kohtla-Järve, increased odds of overdose in the last
12 months were associated with several factors in the
univariate analyses: longer duration of injecting (over 10
years: OR 2.8 95 % CI 1.3–4.3), injecting daily (vs. less
than daily: OR 2.2, 95 % CI 1.4–3.3), injecting fentanyl
(vs. amphetamine: OR 3.2 95 % CI 2.0–5.3), sharing
syringes (OR 3.03, 95 % CI 1.84–4.95), ever being in
prison (OR 2.3 95 % CI 1.5–3.5), and being HIV infected
(OR 1.6 95 % CI 1.1–2.5). Further, problem alcohol use
(OR 1.66, 95 % CI 1.12–2.47) and current mental health
problems (OR 1.77, 95 % CI 1.20–2.60) were associated
with increased odds for overdose. Reporting pharmacy
as the main source of syringes in last 4 weeks was asso-
ciated with decreased odds for overdose (vs NSP: OR
0.44 95 % CI 0.21–0.85).
In St. Petersburg, increased odds of overdose were associ-
ated with the duration of injecting (over 10 years: OR 2.1
95 % CI 1.2–4.0), injecting daily (OR 2.9, 95 % CI 2.0–4.3),
injecting multiple drugs (OR 1.8 95 % CI 1.2–2.6), reporting
non-injecting drug use (OR 2.0 95 % CI 1.0–3.8), sharing
syringes (OR 3.41, 95 % CI 2.04–5.94), reporting pharmacy
as the main source of syringes (vs NSP OR 1.9 95 % CI
1.0–3.7), being HIV infected (OR 1.6, 95 % CI 1.1–2.4). As
in Estonia, both problem alcohol use (OR 3.15, 95 % CI
Table 1 Socio-demographic, injection drug use, HIV prevalence and care and environmental characteristics of current injection drug
users participating and the prevalence of self-reported non lethal overdose within the last 12 months from cross sectional studies in
Kohtla-Järve, Estonia (in 2012) and St Petersburg, Russia (in 2012 – 2013) (Continued)
Ever been in prison p < 0.001 p = 0.368
No 266 45 % 19 % 537 66 % 17 %
Yes 322 55 % 35 % 274 34 % 15 %
Main source of syringes (last 4 weeks) p = 0.0018 p = 0.0121
Needle and syringe program (NSP) 445 77 % 30 % 119 15 % 11 %
Pharmacy 76 13 % 16 % 615 76 % 19 %
Other 26 5 % 35 % 30 4 % 10 %
None 29 5 % 7 % 46 6 % 4 %
Currently receiving drug treatment p > 0.9 p = 0.133
No 216 68 % 32 % 563 97 % 18 %
Yes 102 32 % 32 % 19 3 % 32 %
HIV infection and care
HIV infected p = 0.013 p = 0.021
No 218 37 % 22 % 359 44 % 13 %
Yes 370 63 % 31 % 452 56 % 19 %
Currently on ART p = 0.342 p = 0.051
No 247 67 % 33 % 403 90 % 20 %
Yes 123 33 % 28 % 47 10 % 9 %
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1.91–5.44) and prevalent mental health problems (OR 2.09,
95 % CI 1.40–3.10) were associated with increased odds for
overdose.
Multivariable analysis
Table 2 presents the factors associated with the risk of
overdose within the 12 months prior to interview in
multivariable modelling. The significant factors effects
did not differ for the two sites. In Kohtla-Järve these
were longer duration of injection drug use (over 10
years: AOR 2.77, 95 % CI 1.55–5.08), main drug of injec-
tion (fentanyl vs. amphetamine: AOR 1.70, 95 % CI
1.06–2.72), and sharing (AOR 2.65, 95 % CI 1.6–4.40) in
addition to problem alcohol use (AOR 1.92, 95 % CI
1.25–2.96). In St Petersburg, frequent injecting (AOR
1.75, 95 % CI 1.14–2.69), sharing (AOR 3.09, 95 % CI
1.84–5.40), and problem alcohol use (AOR 2.23, 95 % CI
1.35–3.81) were associated with increased odds for over-
dose. The point estimate for the overdose association
with the use of heroin or methadone as the main drug
of injection (vs amphetamine) – AOR 1.6 (95 % CI
0.36–15.39) – was quite similar to the findings from
Kohtla-Järve. However, the wide confidence interval, re-
lated to the low number of observations in the reference
category of ‘amphetamine’ users, precluded finding a
confidence interval for the AOR that did not include 1.0.
Discussion
This project investigated a subject that has been insuffi-
ciently studied in the countries of the former Soviet
Union: the occurrence of non-fatal overdose and factors
associated with this experience within the last 12
months among current PWID. Two-thirds of current in-
jectors reported ever having experienced a non-fatal
overdose with a significantly higher proportion of PWID
in Kohtla-Järve, Estonia (28 %) than in St. Petersburg,
Russia (16 %) reporting a non-fatal overdose occurring
within the last year.
Although results from studies of non-fatal overdose
across countries are often not easily comparable, as they
may recruit drug users from different settings (popula-
tion based or clinical service based), target populations
(heroin, fentanyl, or pharmaceutical opioid users, prob-
lem drug users, injectors non-injectors), and use differ-
ent recall periods, we have used the same method for
sample recruitment and the same instrument to collect
interview data at contiguous sites separated by a national
border and local differences in the types of drugs
injected. In attempting to compare our results to previ-
ous studies from a range of countries, we found reports
in the literature for lifetime overdose histories ranging
between one-third and two-thirds of heroin users [36].
Our finding that two thirds of current injectors reported
having experienced a non-fatal overdose is clearly at the
higher end of the spectrum. On the other hand, the high
proportion of PWID reporting non-fatal overdose is in
agreement with the high overdose related mortality re-
ported from both Estonia and the Russian Federation.
We also assessed the factors associated with recent
non-fatal overdoses (within the last 12 months). Our
finding of a higher risk of overdose among long-term in-
jectors is in agreement with findings from other studies
[4, 12, 37]. The structural factors, even though different
at the two sites, were not associated with overdose risk
in our analysis. Characteristics of injection drug use
practice (duration, injection frequency, main drug
injected), correlates of high-risk injection behaviour
(sharing) and problem alcohol use were associated with
higher odds for overdose, and significant factors effects
did not differ for the sites.
Higher overdose rates among those injecting more fre-
quently or for more years [21, 38, 39], as well as among
those PWID exhibiting high-risk injection behaviour
(sharing syringes), have been described before [40].
A significantly higher proportion of participants re-
ported overdose experiences in the past 12 months in
Estonia. There are several potential interpretations of
Table 2 Results of multivariable analysis: factors associated with self-reported non fatal overdose within the last 12 months among
current injection drug users in Kohtla-Järve, Estonia (in 2012) and St Petersburg, Russia (in 2012–2013)
Kohtla-Järve (Estonia) St Petersburg (Russia) AORKJ/AORSP
AOR* (95 % CI) AOR* (95 % CI)
Duration of injecting (10+ years) 2.77 (1.55–5.08)*** 1.59 (0.87–3.03) 1.75 (0.72–4.23)
Injecting frequency (daily) 1.44 (0.91–2.27) 1.75 (1.14–2.69)** 0.82 (0.44–1.54)
Main drug injected (opioid)1 1.70 (1.06–2.72)** 1.61 (0.36–15.39) 1.05 (0.10–10.60)
Sharing 2.65 (1.60–4.40)*** 3.09 (1.84–5.40)*** 0.86 (0.40–1.83)
Problem alcohol use 1.92 (1.25–2.96)*** 2.23 (1.35–3.81) *** 0.86 (0.43–1.72)
*OR adjusted for age, sex, main source of income last 6 months, injecting multiple drugs last 4 weeks, non-injecting drug use last 4 weeks, ever been in prison,
ever received drug treatment, main source of syringes last 4 weeks, ever tested for HIV, HIV infected
**p < 0.05, ***p < 0.01
1Using fentanyl or heroin in Kohtla-Järve and fentanyl, heroin or methadone in St. Petersburg defined as ‘opioids as main drug used’ (vs amphetamine use as a
reference group at both sites)
Uusküla et al. BMC Public Health  (2015) 15:1255 Page 6 of 9
this finding. Fluctuations in illicit drug formulations or
purity can have a significant impact on overdose – espe-
cially if periods of low purity alternate with episodes of high
purity. While there were some significant differences in the
socio-demographic and service-utilization characteristics
between the sites, these seem unlikely explanations for the
observed differences in the 12-month overdose risk. Of the
contributors to the overdose risk described in our analysis
the (main injected) drugs of choice were significantly differ-
ent between sites.
In our study, people who reported injecting fentanyl as
their main drug were most likely to report experiencing
overdose. In the European Union, Estonia has the lon-
gest documented epidemic of fentanyl injection among
drug-using populations and formulations of fentanyl re-
main the main injected drugs in Estonia [41, 42]. How-
ever, fentanyl use and the related high levels of mortality
linked with fentanyl are not limited to Estonia. In 2010
and 2011, following heroin shortages, Bulgaria and
Slovakia identified increases in fentanyl use among opi-
oid injectors [41]. Increases in overdose deaths linked
with use of fentanyl have been reported by Germany
[41] and in multiple locations in the USA [43, 44]. Her-
oin dominance was first observed in Estonia in the
early 2000s but was replaced by fentanyl by the mid
2000s [45]. Heroin dominance, which has been sustained
in Russia for some time, has been challenged within the
last few years with the emergence of methadone as an il-
licitly injected drug. If this tendency continues, and there
are further changes in the Russian drug scene, more atten-
tion to a potential increase in overdose rates is needed
from the professional community. We acknowledge that
using information on the main drug injected in the last 4
weeks in the analysis measuring the association of the
drug of choice with the overdose reported over the past
12 months has its limitations. Some of the overdoses re-
ported by participants injecting mainly amphetamines in
the last 4 weeks may have been among those who had also
taken opioids during the last 12 months (and thus have
had an opioid overdose).
The substantial role of alcohol needs to be highlighted,
acknowledging both the high prevalence of problem al-
cohol use among current injectors and the relatively
strong effect for its association with overdose. The
prevalence of problem alcohol use among the male
urban general population in Russia measured using
CAGE scores is reportedly high (23 %) [46], but it
was almost 3 times higher among the current injec-
tion drug users participating in our study (at both
sites). Higher overdose rates associated with alcohol
use among injection drug users have been described
in other studies [47, 48] and may represent pharma-
cological or behavioral interactions between alcohol
and injected substances [36].
We acknowledge that our study has limitations. First
of all, we are describing factors associated with non-fatal
overdose; these might differ from factors that increase
the likelihood of lethal overdoses. The cross-sectional
study design does not allow us to establish causal rela-
tionships nor the direction of the associations described.
The results of the study may have been affected by recall
and social desirability biases. To diminish these potential
biases study participation was anonymous and study
surveys were conducted by trained interviewers in an
environment familiar to the respondents. Although we
used a recruitment methodology (RDS) that has been
shown to provide an efficient sampling technique for
hard-to-reach groups we cannot claim representative-
ness of the study samples.
While these limitations are important, we feel it is ex-
tremely unlikely that they accounted for the patterns
that we observed in the data. Our data were generated
using similar study methods (including recruitment and
measures) and our findings strongly suggest that, in
Kohtla-Järve and in St Petersburg, current PWID are at
high risk for overdose, exhibit high injection risk behav-
iours which, as well as being associated with the risk of
overdose, also contribute to transmission of HIV and
other blood borne infections.
Conclusions
Our results highlight the relevance of the role of drug of
choice and alcohol abuse for observed overdose patterns.
Effective and combined overdose prevention efforts that
also address problem alcohol use and co-occurring mental
health problems, at the public health scale, are warranted
as part of comprehensive harm reduction measures.
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